OTLK
Outlook Therapeutics, Inc.
$1.45
-0.02 (-1.36%)
At close · Jul 2
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$175.25M
Shares
120,863,252
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.45
Open$1.50
Day$1.43–1.63
52W$0.16–3.39
Avg vol 30d33.3M
Short int13.6M · 11.2% float · 1.0d
Short vol45%
Last earningsMay 18, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+60% above
+
Price vs 50-day avg
+92% above
◦
RSI (14)
60 · neutral
−
MACD trend
negative
◦
52-week position
40% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $1 › 200d $1 — 200d above 50d
−
Institutional flow
-2% holders QoQ · +16 funds added
+
Insider flow
Net +$5.3M over 90 days · 0% sells
+
Short interest
11.23% of float · ▼ -15.8% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
56 holders — mid 3-yr range
Fundamentals
Fair
+
Revenue growth
+164% Y/Y
◦
Gross margin
1%
+
EPS growth
+56% Y/Y
−
Free cash flow
$-52.3M
−
Balance sheet
net debt $1.1B
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 17, 2026
Est · unconfirmed
· in 6 wks
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+60% above
Bullish
Price vs 50-day avg
+92% above
Bullish
RSI (14)
60 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
40% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +16 funds added
Insider flow
Accumulating
Net +$5.3M over 90 days · 0% sells
Short interest
Falling
11.23% of float · ▼ -15.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
56 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $1 · 40%
52-wk high $3
vs 200-day avg +60%
vs 50-day avg +92%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OTLK
this stock
Outlook Therapeutics, Inc.
|
$175.25M | -8.2% | +163.8% | — | 11.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OTLK | -9.9% | +79.0% | +140.1% | -8.8% | -8.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -11.4% | +80.3% | +132.1% | -8.5% | -17.5% |